GSA Capital Partners LLP Acquires New Shares in Boston Scientific Corporation $BSX

GSA Capital Partners LLP acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 32,095 shares of the medical equipment provider’s stock, valued at approximately $1,370,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the fourth quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $28,000. Finally, Sfam LLC acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 204,322 shares of company stock valued at $9,939,221 in the last 90 days. 0.34% of the stock is owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Boston Scientific Price Performance

Shares of BSX opened at $51.77 on Monday. The company has a market cap of $75.02 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company’s fifty day simple moving average is $46.06 and its 200 day simple moving average is $59.11. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. TD Cowen lowered their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Finally, UBS Group cut their price target on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.